Matthew B.  Murphy net worth and biography

Matthew Murphy Biography and Net Worth

General Counsel of Nautilus Biotechnology
Matt has spent over a quarter century advising companies on the cutting edge of life sciences technologies. He has held numerous General Counsel roles over this period, including most notably at Pacific Biosciences and 10X Genomics. He specializes in creating and defending industry defining patent portfolios, and in building and leading legal operations that help develop, finance and commercialize high growth companies. Matt received his Bachelor of Science in Microbiology and Fermentation Science from the University of California, Davis, and a Juris Doctorate from the University of San Francisco School of Law.

What is Matthew B. Murphy's net worth?

The estimated net worth of Matthew B. Murphy is at least $141,305.40 as of August 15th, 2022. Mr. Murphy owns 54,140 shares of Nautilus Biotechnology stock worth more than $141,305 as of November 2nd. This net worth approximation does not reflect any other assets that Mr. Murphy may own. Additionally, Mr. Murphy receives an annual salary of $382,640.00 as General Counsel at Nautilus Biotechnology. Learn More about Matthew B. Murphy's net worth.

How old is Matthew B. Murphy?

Mr. Murphy is currently 59 years old. There are 7 older executives and no younger executives at Nautilus Biotechnology. The oldest executive at Nautilus Biotechnology is Ms. Gwen E. Weld, Chief People Officer, who is 66 years old. Learn More on Matthew B. Murphy's age.

What is Matthew B. Murphy's salary?

As the General Counsel of Nautilus Biotechnology, Inc., Mr. Murphy earns $382,640.00 per year. There are 4 executives that earn more than Mr. Murphy. The highest earning executive at Nautilus Biotechnology is Mr. Sujal M. Patel, Co-Founder, CEO, President, Secretary & Director, who commands a salary of $827,240.00 per year. Learn More on Matthew B. Murphy's salary.

How do I contact Matthew B. Murphy?

The corporate mailing address for Mr. Murphy and other Nautilus Biotechnology executives is 51 ASTOR PLACE 10TH FLOOR, NEW YORK NY, 10003. Nautilus Biotechnology can also be reached via phone at 206-333-2001 and via email at [email protected]. Learn More on Matthew B. Murphy's contact information.

Has Matthew B. Murphy been buying or selling shares of Nautilus Biotechnology?

Matthew B. Murphy has not been actively trading shares of Nautilus Biotechnology during the last quarter. Most recently, on Monday, August 15th, Matthew B. Murphy bought 7,500 shares of Nautilus Biotechnology stock. The stock was acquired at an average cost of $2.84 per share, with a total value of $21,300.00. Following the completion of the transaction, the general counsel now directly owns 54,140 shares of the company's stock, valued at $153,757.60. Learn More on Matthew B. Murphy's trading history.

Who are Nautilus Biotechnology's active insiders?

Nautilus Biotechnology's insider roster includes Matthew Mcilwain (Director), Anna Mowry (CFO), Matthew Murphy (General Counsel), Sujal Patel (CEO), and Matthew Posard (Director). Learn More on Nautilus Biotechnology's active insiders.

Are insiders buying or selling shares of Nautilus Biotechnology?

In the last year, Nautilus Biotechnology insiders bought shares 3 times. They purchased a total of 38,303 shares worth more than $108,316.27. In the last year, insiders at the sold shares 2 times. They sold a total of 82,031 shares worth more than $234,728.97. The most recent insider tranaction occured on September, 23rd when VP Mary E. Godwin sold 47,031 shares worth more than $134,978.97. Insiders at Nautilus Biotechnology own 40.5% of the company. Learn More about insider trades at Nautilus Biotechnology.

Information on this page was last updated on 9/23/2024.

Matthew B. Murphy Insider Trading History at Nautilus Biotechnology

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
8/15/2022Buy7,500$2.84$21,300.0054,140View SEC Filing Icon  
8/12/2022Buy2,500$2.85$7,125.0046,640View SEC Filing Icon  
8/13/2021Buy5,000$7.56$37,800.00View SEC Filing Icon  
See Full Table

Matthew B. Murphy Buying and Selling Activity at Nautilus Biotechnology

This chart shows Matthew B Murphy's buying and selling at Nautilus Biotechnology by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Nautilus Biotechnology Company Overview

Nautilus Biotechnology logo
Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. The company develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis. It also offers proteome analysis system, a high-resolution optical imaging system for integrated fluidics and liquid handling sub-system. In addition, the company provides sample preparation, flow cells, multi-affinity probe reagents, and instrument buffers system to perform multi-cycle analysis runs. Nautilus Biotechnology, Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.
Read More

Today's Range

Now: $2.61
Low: $2.60
High: $2.72

50 Day Range

MA: $2.76
Low: $2.48
High: $3.08

2 Week Range

Now: $2.61
Low: $2.19
High: $3.45

Volume

39,043 shs

Average Volume

74,448 shs

Market Capitalization

$327.71 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.22